NBTX
- Nanobiotix S.A.
()
Overview
Company Summary
Nanobiotix S.A. is a French nanomedicine company that specializes in the development and commercialization of innovative nanoparticles for cancer treatment. The company's approach involves leveraging the unique properties of nanoparticles to enhance the effectiveness of radiotherapy, a common cancer treatment.
Nanobiotix's proprietary technology, called NanoXray, uses nanoparticles that can be injected into tumor tissues. These nanoparticles have the ability to absorb X-rays, thereby increasing the tumor's sensitivity to radiation. This process, known as radioenhancement, allows for more precise and efficient targeting of cancer cells while reducing damage to healthy surrounding tissues.
By enhancing the radiotherapeutic effect, Nanobiotix aims to improve treatment outcomes for patients, such as increased tumor shrinkage and better local control. Additionally, their technology has the potential to broaden the range of cancers that can be effectively treated with radiotherapy.
Nanobiotix has conducted extensive preclinical and clinical trials to demonstrate the safety and efficacy of their nanoparticles across various cancer types. They have also collaborated with leading academic institutions and pharmaceutical companies to explore potential applications of their technology beyond radiation therapy.
In summary, Nanobiotix is a biotech company that focuses on the development of nanoparticles to enhance the efficacy of cancer treatment through radiotherapy. Their innovative approach has the potential to revolutionize the field of oncology and improve patient outcomes.